Introduction
Peritoneal carcinomatosis is a major problem after surgery for serosal-invasive gastric cancer because most patients with peritoneal carcinomatosis die within six months of diagnosis°. Gastric carcinoma cells were often detected in the abdominal cavity even when it was not demonstrated macroscopically that patients with serosal-invasive gastric cancer had peritoneal dissemination2). It has been reported that, when an anticancer drug was intraperitoneally administered, a significantly greater concentration was obtained in the abdominal cavity than in the circulating blood2). Therefore, for patients with peritoneal carcinomatosis, intraperitoneal injection of anticancer drugs had been used, but the effectiveness of this method is still unsatisfactory. Intraperitoneal chemohyperthermia increases the sensitivity of tumor cells to anticancer drugs and simultaneously enhances the antigenicity of tumor cells3). Hyperthermia combined with chemotherapy has been introduced for the management of intraperitoneal recurrence after gastrointestinal cancer resection4). In this study, we evaluate the efficacy of intraperitoneal chemohyperthermiafor gastric cancer patients with peritoneal carcinomatosis.
Patients and Methods
From 1999 to 2003, 17 gastric cancer patients with peritoneal carcinomatosis confirmed by cytological and/or pathological examination during operation were treated by removing the primary tumor. All patients underwent a subtotal or total gastrectomy, and 24-Fr silicon tubes were placed in the left subphrenic and Douglas pouch. There were 11 males and six females , and the average age was 
Results
The mean duration of follow-up was 10 months (range 2 to 27 months). Among the 17 patients, cancer recurrence was detected in 12 (70.6%) patients ; all patients had peritoneal recurrences. The disease-free survival curves for the hyperthermia and control groups are shown in Fig. 3 . It has been reported that the patients who underwent intraoperative chemohyperthermia and surgery for serosal-invasive gastric cancer had a higher survival rate and better prognosis than the patients who underwent surgery only. However, patients with peritoneal carcinomatosis confirmed by cytological and/or pathological examination were excluded from the study8).
In this study, we evaluated the efficacy of chemohyperthermia for gastric cancer patients with peritoneal carcinomatosis. Most patients with peritoneal carcinomatosis die within 6 months of diagnosis1). In our study, the 10-month disease-free and overall survival rates for the hyperthermia were 57.1% and 85.
7%, respectively, and were higher than those of the control group. We consider that chemohyperthermia with the removal of the primary tumor can produce a satisfactory therapeutic effect. However, no significant differences were observed in the 10-month survival rates between the two groups because this study was performed with a small number of patients. Therefore, a study that includes a large number of patients will be necessary. Furthermore, in order to prove availability of chemohyperthermia for gastric cancer patients with peritoneal carcinomatosis, we must compare chemohyperthermia with chemotherapy only regarding the overall survival rate.
Although it has been attested that intraoperative chemohyperthermia is an effective procedure, several complications, such as leakage of intestinal anastomosis, intestinal perforation, bone marrow suppression, and renal failure, have been reported9). Therefore, we preformed chemohyperthermia two weeks after surgery, when the general condition of the patients was better. No patient in the hyperthermia group had life-threatening complications. This finding indicates that postoperative chemohyperthermia can be recommended when resection and anastomosis have been performed.
In conclusion, postoperative chemohyperthermia appears to improve the prognosis of gastric cancer 
